What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis

Abstract Objectives There are currently various tyrosine kinase inhibitor (TKI)-based regimens available, and it can be challenging for clinicians to determine the most effective and safe option due to the lack of direct comparisons between these regimens. In this study, we conducted a network meta-...

Повний опис

Бібліографічні деталі

Автори:	Wengang Zhang, Xinyu Zhang, Wencheng Zhao, Zhiyi Guo, Xinyue Liu, Li Ye, Zhimin Chen, Kandi Xu, Yujin Liu, Hao Wang, Lishu Zhao, Qianqian Zhang, Yujie Li, Xuyang Chen, Yayi He
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2024-12-01
Серія:	BMC Pulmonary Medicine
Предмети:	Epidermal growth factor receptor Tyrosine kinase inhibitors Osimertinib Network meta-analysis Non-small cell lung cancer
Онлайн доступ:	https://doi.org/10.1186/s12890-024-03438-3
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!